Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
|2||Active, not recruiting||
Open Label Extension for GLYX13-C-202, NCT01684163
Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
NRX-1074 in Early Course Schizophrenia
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
† Study has passed its completion date and status has not been verified in more than two years.